Report
EUR 13.20 For Business Accounts Only

Due to a more favourable environment, TRUPANION slightly increases to Slightly Negative

TRUPANION (US), a company active in the Life Insurance industry, slightly increases its general evaluation. The independent financial analyst theScreener just confirmed the stock market behaviour of the title as risky. At the fundamental level, theScreener confirms the rating of 0 out of 4 stars; given the more favourable environment, the title's overall rating is upgraded to Slightly Negative even if it remains under pressure. As of the analysis date March 15, 2022, the closing price was USD 76.80 and its target price was estimated at USD 58.49.
Underlying
Trupanion Inc.

Trupanion provides medical insurance for cats and dogs throughout the United States, Canada and Puerto Rico. The company operates in two business segments: subscription business and other business. The subscription business segment includes subscription fees for the company's medical insurance, which the company market to consumers. The other business segment is engaged in writing policies on behalf of third parties.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch